Literature DB >> 19110208

Polycyclic compounds: ideal drug scaffolds for the design of multiple mechanism drugs?

Cornelis J Van der Schyf1, Werner J Geldenhuys.   

Abstract

Recently there has been a resurging interest in developing multi-functional drugs to treat diseases with complex pathological mechanisms. Such drug molecules simultaneously target multiple etiologies that have been found to be important modulators in specific diseases. This approach has significant promise and may be more effective than using one compound specific for one drug target or, by a polypharmaceutical approach, using a cocktail of two or more drugs. Polycyclic ring structures are useful as starting scaffolds in medicinal chemistry programs to develop multi-functional drugs, and may also be useful moieties added to existing structures to improve the pharmacokinetic properties of drugs currently used in the clinic or under development. This review attempts to provide a synopsis of current published research to exemplify the use of polycyclic compounds as starting molecules to develop multi-functional drugs.

Mesh:

Substances:

Year:  2009        PMID: 19110208      PMCID: PMC5084265          DOI: 10.1016/j.nurt.2008.10.037

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  71 in total

1.  Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2+) channels.

Authors:  N N Lermontova; A E Redkozubov; E F Shevtsova; T P Serkova; E G Kireeva; S O Bachurin
Journal:  Bull Exp Biol Med       Date:  2001-11       Impact factor: 0.804

2.  Trishomocubanes: novel sigma ligands modulate cocaine-induced behavioural effects.

Authors:  Xiang Liu; Samuel D Banister; MacDonald J Christie; Richard Banati; Steve Meikle; Mark J Coster; Michael Kassiou
Journal:  Eur J Pharmacol       Date:  2006-10-18       Impact factor: 4.432

3.  Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.

Authors:  Shunit Gal; Hailin Zheng; Mati Fridkin; Moussa B H Youdim
Journal:  J Neurochem       Date:  2005-10       Impact factor: 5.372

4.  Comparison of binding parameters of sigma 1 and sigma 2 binding sites in rat and guinea pig brain membranes: novel subtype-selective trishomocubanes.

Authors:  V H Nguyen; M Kassiou; G A Johnston; M J Christie
Journal:  Eur J Pharmacol       Date:  1996-09-12       Impact factor: 4.432

5.  A novel pharmacological approach to treating cardiac ischemia. Binary conjugates of A1 and A3 adenosine receptor agonists.

Authors:  K A Jacobson; R Xie; L Young; L Chang; B T Liang
Journal:  J Biol Chem       Date:  2000-09-29       Impact factor: 5.157

Review 6.  The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.

Authors:  Moussa B H Youdim
Journal:  Curr Alzheimer Res       Date:  2006-12       Impact factor: 3.498

7.  Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS).

Authors:  Yanqi Liang; Amanda M Shaw; Mona Boules; Siobhan Briody; Jessica Robinson; Alfredo Oliveros; Eric Blazar; Katrina Williams; Yiqun Zhang; Paul R Carlier; Elliott Richelson
Journal:  J Pharmacol Exp Ther       Date:  2008-08-08       Impact factor: 4.030

8.  Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase.

Authors:  M Naoi; W Maruyama; M B H Youdim; P Yu; A A Boulton
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

9.  6-(2-adamantan-2-ylidene-hydroxybenzoxazole)-O-sulfamate: a potent non-steroidal irreversible inhibitor of human steroid sulfatase.

Authors:  Erwin P Schreiner; Barbara Wolff; Anthony P Winiski; Andreas Billich
Journal:  Bioorg Med Chem Lett       Date:  2003-12-15       Impact factor: 2.823

10.  Synthesis and biological activity of D3-trishomocubyl-4-amines.

Authors:  D W Oliver; T G Dekker; F O Snyckers; T G Fourie
Journal:  J Med Chem       Date:  1991-02       Impact factor: 7.446

View more
  6 in total

1.  1-Adamantylmethyl 2-amino-benzoate.

Authors:  Zuzana Kozubková; Michal Rouchal; Marek Nečas; Robert Vícha
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-11-20

2.  1-(2-Phenyl-eth-yl)adamantane.

Authors:  Michal Rouchal; Marek Nečas; Robert Vícha
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-06-23

3.  2-(1-Adamant-yl)-1-(3-amino-phen-yl)ethanol.

Authors:  Michal Rouchal; Zuzana Kozubková; Marek Nečas; Robert Vícha
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-08-27

4.  Diels-Alder reactions between cyclopentadiene analogs and benzoquinone in water and their application in the synthesis of polycyclic cage compounds.

Authors:  Yijun Shi; Xuejing Liu; Ying Han; Peng Yan; Fusheng Bie; Han Cao
Journal:  RSC Adv       Date:  2020-01-02       Impact factor: 3.361

5.  Synthesis and Biological Evaluations of NO-Donating Oxa- and Aza-Pentacycloundecane Derivatives as Potential Neuroprotective Candidates.

Authors:  Rajan Sharma; Jacques Joubert; Sarel F Malan
Journal:  Molecules       Date:  2018-01-31       Impact factor: 4.411

6.  4-Oxatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione Derivatives as NMDA Receptor- and VGCC Blockers with Neuroprotective Potential.

Authors:  Ayodeji O Egunlusi; Sarel F Malan; Sylvester I Omoruyi; Okobi E Ekpo; Jacques Joubert
Journal:  Molecules       Date:  2020-10-05       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.